Affinage

CALD1

Caldesmon · UniProt Q05682

Round 2 corrected
Length
793 aa
Mass
93.2 kDa
Annotated
2026-04-28
70 papers in source corpus 15 papers cited in narrative 15 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CALD1 (caldesmon) is an actin- and calmodulin-binding cytoskeletal regulatory protein that controls smooth muscle contractility and non-muscle cell motility by modulating F-actin stress fiber stability and focal adhesion dynamics. In smooth muscle, its C-terminal domain binds F-actin, tropomyosin, and calmodulin, and phosphorylation by MAP kinase or ERK1/2 attenuates its actin interaction, relieving actin-filament inhibition and permitting contraction or cytoskeletal remodeling (PMID:1331069, PMID:36230524). In non-muscle and cancer contexts, CALD1 expression is regulated post-transcriptionally by METTL14-mediated m6A methylation and miRNAs (miR-1278, miR-148a-5p), and CALD1 signals through PI3K-Akt, MAPK, and JAK/STAT pathways to influence epithelial–mesenchymal transition, invasion, and immune checkpoint (PD-L1) expression (PMID:37017680, PMID:38025524, PMID:34733993, PMID:38577446). Tumor-specific alternative splicing of CALD1 occurs across multiple cancer types and in glioma microvasculature, yielding isoforms with potentially altered function (PMID:18353764, PMID:15161654).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 1992 High

    Identifying how caldesmon's actin-regulatory activity is switched off resolved a long-standing question about the kinase signal that controls smooth muscle thin-filament regulation: MAP kinase phosphorylates the C-terminal actin-binding domain and selectively weakens the caldesmon–actin interaction without disrupting calmodulin or tropomyosin binding.

    Evidence In vitro phosphorylation of purified chicken gizzard caldesmon by sea-star p44mpk; tryptic peptide mapping; actin/calmodulin/tropomyosin co-sedimentation assays; immunoprecipitation of endogenous MAP kinase from rat aorta smooth muscle

    PMID:1331069

    Open questions at the time
    • In vivo phosphorylation sites not mapped at single-residue resolution in this study
    • Structural basis of how phosphorylation weakens actin binding not determined
    • Whether additional kinases (e.g. p34cdc2) phosphorylate the same or distinct sites in smooth muscle not addressed
  2. 2000 Medium

    Establishing that caldesmon participates in PAK1-dependent cytoskeletal remodeling in invasive breast cancer cells extended its role beyond smooth muscle contraction to cancer cell motility: kinase-dead PAK1 traps caldesmon and tropomyosin on stabilized stress fibers, blocking invasion.

    Evidence Overexpression of kinase-dead PAK1(K299R) in MDA-MB435 and MDA-MB231 cells; immunofluorescence co-localization of caldesmon/tropomyosin with F-actin; invasion assays

    PMID:10766836

    Open questions at the time
    • Whether PAK1 directly phosphorylates caldesmon was not tested
    • Caldesmon was not knocked down to confirm it is required for PAK1-dependent invasion
  3. 2004 Medium

    Discovery of tumor-specific CALD1 splice variants in glioma and subsequently in colon, bladder, and prostate cancers revealed that alternative splicing diversifies caldesmon function in the tumor microenvironment and may alter its actin-regulatory properties.

    Evidence Laser-capture microdissection of glioma versus normal microvessels with RT-PCR splice-variant identification; GeneChip Exon Array across 102 samples with RT-PCR validation in 81 independent samples

    PMID:15161654 PMID:18353764

    Open questions at the time
    • Functional consequences of cancer-specific splice variants on actin binding or contractility not experimentally validated
    • Whether splice variants are causative or merely correlative in tumor progression remains untested
  4. 2007 Medium

    Subcellular mapping of the low-molecular-weight caldesmon isoform to motility-associated protrusions (filopodia, lamellipodia, podosomes, membrane blebs) in tumor-associated endothelial cells specified the cellular compartment in which caldesmon operates during tumor angiogenesis.

    Evidence Immunohistochemistry on multiple human tumor types identifying l-CaD in endothelial and endothelial progenitor cell protrusion subtypes

    PMID:19329885

    Open questions at the time
    • Loss-of-function in endothelial protrusions not performed
    • Whether l-CaD is required for protrusion formation or merely accumulates there is unknown
  5. 2021 Medium

    Placing CALD1 upstream of JAK/STAT-mediated PD-L1 expression in bladder cancer expanded its role from a cytoskeletal regulator to a modulator of immune checkpoint signaling, as pharmacological JAK inhibition (Ruxolitinib) blocked CALD1-driven PD-L1 upregulation.

    Evidence CALD1 overexpression/knockdown in bladder cancer cells; JAK inhibitor rescue; nude mouse xenograft; GSEA pathway analysis

    PMID:34733993

    Open questions at the time
    • Direct physical interaction between CALD1 and JAK pathway components not demonstrated
    • Whether the JAK/STAT link operates in non-bladder cancer contexts is unknown
  6. 2022 Medium

    Epistasis experiments showed CALD1 is a functional effector downstream of the AHSA1–ERK axis in hepatocellular carcinoma EMT: CALD1 knockdown rescued the proliferation and EMT inhibition caused by AHSA1 depletion, and ERK inhibitor SCH772984 reversed AHSA1-driven CALD1 phosphorylation.

    Evidence Double knockdown epistasis (AHSA1 + CALD1); ERK1/2 inhibitor rescue; in vitro and in vivo HCC models; western blot for phospho-CALD1

    PMID:36230524

    Open questions at the time
    • Specific ERK phosphorylation sites on CALD1 not mapped in this system
    • Whether CALD1's actin-binding function is required for the EMT phenotype not tested
  7. 2023 Medium

    Identification of post-transcriptional regulators of CALD1 — m6A methylation by METTL14 and direct miR-1278 targeting of the 3′UTR — established that CALD1 expression is tuned at the mRNA level in cancer, with functional consequences for MAPK pathway activation and tumor growth.

    Evidence MeRIP assay for m6A on CALD1 mRNA with METTL14 knockdown/rescue in OSCC; dual luciferase reporter assay validating miR-1278 binding to CALD1 3′UTR in gastric cancer; xenograft models

    PMID:37017680 PMID:38025524

    Open questions at the time
    • Specific m6A sites on CALD1 mRNA not mapped at nucleotide resolution
    • Whether METTL14 and miR-1278 regulation operates simultaneously or in different cellular contexts is unknown
  8. 2024 Medium

    CALD1 was shown to drive EMT and invasion in gastric cancer specifically through PI3K-Akt-mTOR signaling, with pathway inhibitor rescue confirming directionality; separately, endothelin-1 was identified as an upstream inducer of high-molecular-weight CALD1 in placental smooth muscle, linking CALD1 to vasoconstriction in preeclampsia.

    Evidence PI3K-Akt inhibitor rescue of CALD1 overexpression phenotypes in GC cells and xenografts; ET-1 receptor antagonism in placental veins and HUVSMCs with vasocontraction measurements

    PMID:38577446 PMID:39476475

    Open questions at the time
    • How CALD1, an actin-binding protein, activates PI3K-Akt remains mechanistically undefined
    • Whether ET-1-induced CALD1 upregulation is transcriptional or post-translational not determined
  9. 2025 Medium

    Two studies completed the picture of CALD1's context-dependent role: in ovarian cancer, CALD1 knockdown reduced F-actin stress fibers and focal adhesions, paradoxically increasing invasion; in gastric cancer CAFs, H. pylori-driven TLR signaling suppresses miR-148a-5p to upregulate CALD1, which drives collagen VI secretion and paracrine proliferative signaling through tumoral SDC4.

    Evidence Stable shRNA knockdown in SK-OV-3 with F-actin/Vinculin immunofluorescence and invasion assays; miR-148a-5p agomir in CAF-GC co-culture and PDX/CDX mouse models

    PMID:40104711 PMID:41171370

    Open questions at the time
    • Opposing invasion phenotypes in ovarian cancer versus other tumor types not reconciled mechanistically
    • How CALD1 regulates collagen VI secretion in CAFs is unknown
    • Whether the miR-148a-5p/CALD1/collagen VI/SDC4 axis operates outside gastric cancer is untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • A unifying structural and signaling model explaining how a single actin-binding protein exerts context-dependent pro- or anti-invasive effects across different cell types, and how its cytoskeletal function connects to downstream transcriptional pathway activation (JAK/STAT, PI3K-Akt, MAPK), remains to be established.
  • No high-resolution structure of caldesmon bound to F-actin available
  • Direct mechanism linking CALD1 to activation of PI3K-Akt, JAK/STAT, and MAPK transcriptional programs is unknown
  • Relative contribution of individual phosphorylation sites (ERK, p34cdc2, PAK1) to distinct phenotypic outputs has not been dissected in a single system

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 4 GO:0098772 molecular function regulator activity 4
Localization
GO:0005856 cytoskeleton 4 GO:0005829 cytosol 2 GO:0005886 plasma membrane 1
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-397014 Muscle contraction 2 R-HSA-1474244 Extracellular matrix organization 1
Partners
ACTA2AHSA1CALM1MAPK1METTL14PAK1TPM1

Evidence

Reading pass · 15 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1992 Smooth muscle caldesmon (CALD1) is phosphorylated in vitro by MAP kinase (p44mpk) at up to 2.0 mol phosphate/mol protein at Ser and Thr residues located predominantly in the C-terminal 10-kDa fragment that houses binding sites for calmodulin, tropomyosin, and F-actin. Phosphorylation attenuated caldesmon's interaction with actin but did not affect its binding to calmodulin or tropomyosin. Differentiated smooth muscle cells (chicken gizzard, rat aorta) contain endogenous MAP kinase that immunoprecipitates with caldesmon-directed kinase activity, establishing MAP kinase as a writer of caldesmon phosphorylation in smooth muscle. In vitro phosphorylation assay with purified sea-star p44mpk, tryptic peptide mapping of 32P-labeled caldesmon, actin/calmodulin/tropomyosin binding assays post-phosphorylation, immunoprecipitation of endogenous MAP kinase from smooth muscle extracts The Journal of Biological Chemistry High 1331069
2000 Kinase-dead PAK1 (K299R) stabilizes actin stress fibers in invasive breast cancer cells in part through persistent co-localization with caldesmon (CALD1) and tropomyosin on F-actin filaments. Loss of PAK1 activity prevents stress fiber disassembly and reduces invasiveness, placing caldesmon downstream of PAK1 signaling in cytoskeletal remodeling during cancer cell invasion. Overexpression of kinase-dead K299R PAK1 in MDA-MB435 and MDA-MB231 cells; immunofluorescence co-localization of caldesmon and tropomyosin with F-actin; focal adhesion and invasion assays The Journal of Biological Chemistry Medium 10766836
2004 Differential splicing of CALD1 exons occurs in glioma microvasculature versus normal brain microvasculature. Missplicing involving exons 1, 1+4, and 1'+4 is exclusive to tumor microvessels and results in upregulated caldesmon protein expression. This transcriptional/splicing change co-exists with downregulation of tight junction proteins occludin and ZO-1, implicating CALD1 missplicing as an epigenetic event contributing to endothelial barrier dysfunction in glioma. Laser-capture microdissection of tumor and normal microvessels, RT-PCR for splice variants, coupled in vitro transcription/translation assay (IVTT) for mutation scanning, immunohistochemistry for caldesmon, occludin, and ZO-1 The American Journal of Pathology Medium 15161654
2007 The low-molecular-weight caldesmon isoform (Hela l-CaD) localizes specifically to motility-related cell protrusions — filopodia, microspikes, lamellipodia, podosomes, membrane blebs, and membrane ruffles — in activated endothelial cells and endothelial progenitor cells within human tumor vasculature, implicating this isoform in EC/EPC migration during tumor angiogenesis and vasculogenesis. Immunohistochemistry on histologically preserved tumor microenvironment sections from multiple human tumor types; subcellular localization of Hela l-CaD to identified protrusion subtypes Cell Adhesion & Migration Medium 19329885
2008 Tumor-specific alternative splicing of CALD1 is identified across colon, bladder, and prostate cancers, representing a general cancer-related splicing event. In silico protein predictions indicate that cancer-specific CALD1 splice variants encode proteins with potentially altered functions, suggesting involvement in cancer pathogenesis. GeneChip Human Exon 1.0 ST Array on 102 normal and cancer tissue samples; RT-PCR validation on independent set of 81 normal and tumor samples; in silico protein structure prediction Molecular & Cellular Proteomics Medium 18353764
2021 CALD1 modulates glioma progression by facilitating tumor angiogenesis. Single-cell RNA-seq and bulk RNA-seq analyses demonstrate CALD1 upregulation in neoplastic cells, and histology/immunofluorescence shows CALD1 association with vessel architecture. CALD1 expression correlates with endothelial cell and pericyte infiltration in the tumor microenvironment. Bulk RNA-seq and single-cell RNA-seq (TCGA, CGGA databases), immunofluorescence, histological analysis of vessel architecture Cancers Low 34070840
2021 CALD1 promotes PD-L1 (CD274) expression in bladder cancer via activation of the JAK/STAT signaling pathway. CALD1 overexpression upregulates PD-L1, and this effect is blocked by the specific JAK inhibitor Ruxolitinib, placing CALD1 upstream of JAK/STAT-mediated immune checkpoint regulation. WGCNA gene network analysis; CCK-8, flow cytometry, Transwell assays; nude mouse xenograft; JAK inhibitor (Ruxolitinib) rescue experiment; GSEA pathway analysis; correlation analysis with TIMER database Annals of Translational Medicine Medium 34733993
2021 Linggui Zhugan decoction (LGZGD) improves insulin resistance in vivo (HFD rats) and in vitro (TNF-α-treated 3T3-L1 adipocytes) by downregulating Cald1 expression. Knockdown of Cald1 is associated with increased insulin-stimulated glucose uptake, identifying CALD1 as a novel regulator of insulin sensitivity in adipocytes. Gene microarray to identify DEGs in HFD vs. LGZGD-treated rats; qRT-PCR validation; 3H-2-DG glucose uptake assay in IR 3T3-L1 adipocytes; Oil Red O staining Journal of Traditional Chinese Medicine Low 34708628
2022 AHSA1 promotes proliferation and epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma through an ERK/CALD1 axis. AHSA1 recruits ERK1/2 and promotes phosphorylation (inactivation) of CALD1; ERK1/2 phosphorylation inhibitor SCH772984 reverses the effect of AHSA1 on proliferation and EMT. CALD1 knockdown rescues the inhibition of proliferation and EMT caused by AHSA1 knockdown, placing CALD1 as a downstream effector of AHSA1-ERK signaling independent of HSP90 and MEK1/2. Gain- and loss-of-function studies in vitro and in vivo; ERK1/2 inhibitor (SCH772984) rescue; CALD1 knockdown epistasis; western blot for phospho-CALD1 Cancers Medium 36230524
2023 miR-1278 directly targets CALD1 mRNA (confirmed by dual luciferase reporter assay) and negatively regulates its expression. CALD1 overexpression promotes gastric cancer cell viability and migration and activates the MAPK pathway (Ras, p-P38, p-ERK1/2). miR-1278 mimic partially rescues the pro-tumorigenic effects of CALD1 overexpression, placing CALD1 as a downstream target of miR-1278 in the miR-1278/CALD1/MAPK axis. Dual luciferase reporter assay (miR-1278 targeting CALD1 3'UTR); CCK-8 and Transwell migration assays; western blot for MAPK pathway proteins; tumor xenograft assay Open Medicine Medium 38025524
2023 METTL14-mediated m6A methylation regulates CALD1 mRNA levels in oral squamous cell carcinoma. METTL14 silencing depletes both mRNA and m6A levels of CALD1 (confirmed by MeRIP assay), and CALD1 overexpression rescues the growth and metastasis inhibition caused by METTL14 knockdown, identifying METTL14 as an m6A writer that stabilizes CALD1 mRNA to promote OSCC progression. MeRIP (m6A RNA immunoprecipitation) assay; qRT-PCR and western blot; colony formation and Transwell assays; tumorigenicity assay in vivo; CALD1 OE rescue of si-METTL14 Journal of Environmental Pathology, Toxicology and Oncology Medium 37017680
2024 CALD1 promotes EMT and invasiveness in gastric cancer via the PI3K-Akt signaling pathway. CALD1 overexpression increases PI3K, p-AKT, and p-mTOR expression and decreases PTEN; PI3K-Akt inhibitor treatment attenuates CALD1-driven cell migration, invasion, and EMT marker changes. Animal xenograft experiments confirm that CALD1 inhibition slows tumor growth with corresponding changes in PI3K-Akt and EMT pathway proteins. CALD1 siRNA knockdown and overexpression in AGS and MKN45 GC cells; CCK-8, wound healing, Transwell assays; western blot for PI3K/p-AKT/p-mTOR/PTEN; PI3K-Akt inhibitor rescue; GC xenograft mouse model World Journal of Gastrointestinal Oncology Medium 38577446
2024 Endothelin-1 (ET-1) increases high-molecular-weight CALD1 (a marker of the contractile phenotype of smooth muscle cells) in placental chorionic plate vessels and human umbilical vein smooth muscle cells (HUVSMC) via ETAR and ETBR receptors. This increase in CALD1 is associated with stronger vasoconstriction in preeclamptic placental veins, independent of CaV1.2 channel activity. Vasocontraction measurements (DMT) with ET-1, receptor antagonists, and CaV1.2 blockers; whole-cell patch clamp for CaV1.2 in single SMCs; PCR, western blot, ELISA for CALD1 and receptor expression; placental vessel explants and HUVSMC ET-1 treatment with/without antagonists Placenta Medium 39476475
2025 CALD1 knockdown in SK-OV-3 ovarian cancer cells reduces F-actin stress fibers, loosens cytoskeletal structure, decreases Vinculin expression, and reduces focal adhesion number, resulting in enhanced cell migration and invasiveness. This establishes CALD1 as a regulator of cytoskeletal organization and focal adhesion formation that suppresses ovarian cancer cell invasion. Stable CALD1 shRNA knockdown in SK-OV-3 cells; Transwell invasion assay; immunofluorescence staining of F-actin and Vinculin; western blot Translational Cancer Research Medium 40104711
2025 In Helicobacter pylori-stimulated cancer-associated fibroblasts (CAFs), TLR signaling suppresses miR-148a-5p, leading to upregulation of CALD1 in CAFs. CALD1 upregulation drives collagen VI secretion from CAFs, which interacts with tumoral SDC4 receptors to promote gastric cancer cell proliferation. miR-148a-5p agomir inhibits this pathway in vivo and enhances chemotherapy efficacy. microRNA and transcriptome analysis; single-cell sequencing; in vitro CAF-GC co-culture; cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models; miR-148a-5p agomir treatment Cellular Oncology Medium 41171370

Source papers

Stage 0 corpus · 70 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2006 Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2861 17081983
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
2015 A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 1015 26496610
2018 VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell discovery 829 29507755
2003 Complete sequencing and characterization of 21,243 full-length human cDNAs. Nature genetics 754 14702039
2012 A census of human soluble protein complexes. Cell 689 22939629
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
2021 Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature 532 33845483
2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome research 438 15489334
2022 OpenCell: Endogenous tagging for the cartography of human cellular organization. Science (New York, N.Y.) 432 35271311
2010 Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science (New York, N.Y.) 421 20360068
2005 Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome research 409 16344560
1996 Normalization and subtraction: two approaches to facilitate gene discovery. Genome research 401 8889548
2013 Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. Science signaling 383 24255178
2005 Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proceedings of the National Academy of Sciences of the United States of America 383 16009940
2007 Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proceedings of the National Academy of Sciences of the United States of America 360 17620599
2001 Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 359 11518968
2021 A proximity-dependent biotinylation map of a human cell. Nature 339 34079125
2003 Smooth muscle contraction and relaxation. Advances in physiology education 322 14627618
2017 Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proceedings of the National Academy of Sciences of the United States of America 282 28611215
2012 A high-throughput approach for measuring temporal changes in the interactome. Nature methods 273 22863883
2004 Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation. Nature biotechnology 266 15146197
2013 PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry. Molecular cell 204 24332808
2020 Systems analysis of RhoGEF and RhoGAP regulatory proteins reveals spatially organized RAC1 signalling from integrin adhesions. Nature cell biology 194 32203420
2008 Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Molecular & cellular proteomics : MCP 183 18353764
2014 E-cadherin interactome complexity and robustness resolved by quantitative proteomics. Science signaling 162 25468996
2019 A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape. Nature immunology 159 30833792
2003 First-second shell interactions in metal binding sites in proteins: a PDB survey and DFT/CDM calculations. Journal of the American Chemical Society 159 12617685
2000 Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. The Journal of biological chemistry 157 10766836
2022 The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nature cell biology 122 35013556
1992 Phosphorylation of smooth muscle caldesmon by mitogen-activated protein (MAP) kinase and expression of MAP kinase in differentiated smooth muscle cells. The Journal of biological chemistry 120 1331069
2017 The human cytoplasmic dynein interactome reveals novel activators of motility. eLife 118 28718761
2002 Factors governing the protonation state of cysteines in proteins: an Ab initio/CDM study. Journal of the American Chemical Society 84 12047197
2002 The CDM protein DOCK2 in lymphocyte migration. Trends in cell biology 77 12191913
1999 Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins. Biochimica et biophysica acta 74 10559471
1999 Leishmania spp: completely defined medium without serum and macromolecules (CDM/LP) for the continuous in vitro cultivation of infective promastigote forms. The American journal of tropical medicine and hygiene 55 9988320
2004 Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature. The American journal of pathology 50 15161654
2006 A DFT/CDM Study of metal-carboxylate interactions in metalloproteins: factors governing the maximum number of metal-bound carboxylates. Journal of the American Chemical Society 47 16448126
2006 The CDM superfamily protein MBC directs myoblast fusion through a mechanism that requires phosphatidylinositol 3,4,5-triphosphate binding but is independent of direct interaction with DCrk. Molecular and cellular biology 35 17030600
2008 Mononuclear versus binuclear metal-binding sites: metal-binding affinity and selectivity from PDB survey and DFT/CDM calculations. Journal of the American Chemical Society 32 18303888
2000 Refining the mouse chromosomal location of Cdm, the major gene associated with susceptibility to cadmium-induced testicular necrosis. Pharmacogenetics 29 10762002
2021 CALD1 Modulates Gliomas Progression via Facilitating Tumor Angiogenesis. Cancers 23 34070840
2021 CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway. Annals of translational medicine 22 34733993
2019 An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PloS one 19 31188831
2007 Consensus Data Mining (CDM) Protein Secondary Structure Prediction Server: combining GOR V and Fragment Database Mining (FDM). Bioinformatics (Oxford, England) 19 17660202
2007 Hela l-CaD is implicated in the migration of endothelial cells/endothelial progenitor cells in human neoplasms. Cell adhesion & migration 18 19329885
2022 Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM. Scientific reports 17 35292697
2021 Quantitative Expression of TYR, CD34, and CALD1 Discriminates Between Canine Oral Malignant Melanomas and Soft Tissue Sarcomas. Frontiers in veterinary science 17 34422947
2009 Metal-binding affinity and selectivity of nonstandard natural amino acid residues from DFT/CDM calculations. The journal of physical chemistry. B 17 19642664
2022 AHSA1 Promotes Proliferation and EMT by Regulating ERK/CALD1 Axis in Hepatocellular Carcinoma. Cancers 16 36230524
2004 Oxyanion selectivity in sulfate and molybdate transport proteins: an ab initio/CDM study. Journal of the American Chemical Society 14 15315443
2006 Competition between protein ligands and cytoplasmic inorganic anions for the metal cation: a DFT/CDM study. Journal of the American Chemical Society 11 16895422
2023 MYLK and CALD1 as molecular targets in bladder cancer. Medicine 8 38013282
2024 CALD1 facilitates epithelial-mesenchymal transition progression in gastric cancer cells by modulating the PI3K-Akt pathway. World journal of gastrointestinal oncology 6 38577446
2020 Cell-derived matrices (CDM)-Methods, challenges and applications. Methods in cell biology 6 32222221
2016 In silico CDM model sheds light on force transmission in cell from focal adhesions to nucleus. Journal of biomechanics 5 27298154
2024 Endothelin-1 potentiated constriction in preeclampsia placental veins: Role of ETAR/ETBR/CaV1.2/CALD1. Placenta 4 39476475
2023 METTL14 Promotes Oral Squamous Cell Carcinoma Progression by Regulating the mRNA and m6A Levels of CALD1. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 4 37017680
2023 MiR-1278 targets CALD1 and suppresses the progression of gastric cancer via the MAPK pathway. Open medicine (Warsaw, Poland) 4 38025524
2017 Predicting Protein Secondary Structure Using Consensus Data Mining (CDM) Based on Empirical Statistics and Evolutionary Information. Methods in molecular biology (Clifton, N.J.) 4 27787818
2017 Association of rs 3807337 polymorphism of CALD1 gene with diabetic nephropathy occurrence in type 1 diabetes - preliminary results of a family-based study. Endokrynologia Polska 4 28255976
2025 Comprehensive Evaluation of Treatment Patterns in Postmenopausal Patients with Osteoporosis without Fractures: Insights from Tertiary Care Institutions and Nationwide OMOP-CDM Data. Endocrinology and metabolism (Seoul, Korea) 2 40426310
2022 Perceived Risk of Re-Identification in OMOP-CDM Database: A Cross-Sectional Survey. Journal of Korean medical science 2 35790207
2021 Identification of Cald1 as a novel regulator of Linggui Zhugan decoction for improving insulin resistance in vivo and in vitro. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 2 34708628
2025 CALD1 inhibits invasion of human ovarian cancer cells by affecting cytoskeletal structure and the number of focal adhesion. Translational cancer research 1 40104711
2025 Design and fabrication of pH-responsive charge-switchable PEG-CDM-PAMAM nanoassemblies to improve tumor therapy. International journal of pharmaceutics 1 40516771
2025 Identifying patients with neurofibromatosis type 1 related optic pathway glioma using the OMOP CDM. European journal of medical genetics 0 40107446
2025 CALD1-derived circ-0003746 targeting miR-526b promotes EMT-mediated bladder cancer progression. Experimental cell research 0 40818763
2025 Cancer-associated fibroblast miR-148a-5p/CALD1/collagen VI pathway promotes proliferation in Helicobacter pylori-positive gastric cancer. Cellular oncology (Dordrecht, Netherlands) 0 41171370
2014 Free vibration analysis of DWCNTs using CDM and Rayleigh-Schmidt based on Nonlocal Euler-Bernoulli beam theory. TheScientificWorldJournal 0 24715807